Recent Stories
American Biotech — The Future Can’t Be Won Without It.RSI is AI Building AI. What DC needs to know about it. Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: Robots

The Wave

Senatein sessionHousein session
Refreshed just now
News

https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/regulations-guidance-policy-documents

Why it’s here: This CMS page covers the Medicare Drug Price Negotiation Program final rule, guidance, and information collections, which is federal drug-pricing policy directly affecting biotechnology innovation (biosimilar delays, small biotech exceptions), so it is policy-relevant to the biotechnology area.

Trace across the board

Item

Connected

6 links

About

  • Inflation Reduction Act
  • Office of Management and Budget
  • Centers for Medicare & Medicaid Services
  • Inflation Reduction Act drug price negotiation

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy